Latest Breaking News On - Prognosis after relapse - Page 1 : comparemela.com

Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.

United statesDana farber cancer instituteNoord hollandAndrea necchiMichiel simonBradley alexander mcgregorLank centerScientific instituteSalute san raffaele universityAmerican society of clinical oncologyNetherlands cancer instituteVita salute san raffaele universityRaffaele hospitalGenitourinary cancers symposiumAmerican societyGenitourinary oncology